Moran, Lauren V.
Stoeckel, Luke E.
Wang, Kristina
Caine, Carolyn E.
Villafuerte, Rosemond
Calderon, Vanessa
Baker, Justin T.
Ongur, Dost
Janes, Amy C.
Evins, A. Eden
Pizzagalli, Diego A.
Funding for this research was provided by:
National Institute of Mental Health (K23 MH110564, R01 MH068376, R37 MH068376)
National Institute on Drug Abuse (K24 DA030443)
National Alliance for Research on Schizophrenia and Depression (20558)
Dupont-Warren Fellowship, Harvard Medical School, Dept. Psychiatry
Pope-Hintz Fellowship, McLean Hospital
Article History
Received: 15 June 2017
Accepted: 20 November 2017
First Online: 27 November 2017
Compliance with ethical standards
:
: Over the past 3 years, Dr. Pizzagalli has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer, and Posit Science for activities unrelated to the current study. Dr. Evins has received research grant awards to her institution from Pfizer, Forum Pharmaceuticals, and GlaxoSmithKline and has received consulting fees from Pfizer and Reckitt Benckiser. All other authors declare that they have no conflicts of interest.